Haematologica 1995; 80: 512–517. 27 Huijgens PC, Simoons-Smit Entinostat supplier AM, van Loenen AC et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol 1999; 52: 376–380. 28 Morgenstern GR, Prentice AG, Prentice HG et al. A randomized controlled trial of itraconazole versus fluconazole

for the prevention of fungal infections in patients with haematological malignancies. UK Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999; 105: 901–911. 29 Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 70–713. 30 Marr KA, Crippa F, Leisenring W et al.

Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527–1533. 31 Oren I, Rowe JM, Sprecher H et al. A prospective randomized trial of itraconazole vs fluconazole SAHA HDAC clinical trial for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006; 38: 127–134. 32 Glasmacher A, Cornely O, Ullmann AJ et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Progesterone Chemother 2006; 57: 317–325. 33 Moriyama B, Henning SA, Leung J et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses 2012; 55: 290–297. 34 Cornely OA, Maertens J, Winston DJ et al. Posaconazole

vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348–359. 35 Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335–347. 36 Wingard JR, Carter SL, Walsh TJ et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116: 5111–5118. 37 McCarthy KL, Playford EG, Looke DF, Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 2007; 44: e55–56. 38 Cowen EW, Nguyen JC, Miller DD et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010; 62: 31–37. 39 Miller DD, Cowen EW, Nguyen JC et al. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol 2010; 146: 300–304. 40 Kuritzkes DR, Parenti D, Ward DJ et al.